Related Experiment Video
Updated: Apr 16, 2026
Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
Published on: May 13, 2021
Treatment of human thyroid carcinoma cells with the g47delta oncolytic herpes simplex virus
Jia-Ni Wang1, Li-Hua Xu, Wei-Gen Zeng
1Breast Cancer Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Background:
Thyroid carcinoma is the most common malignancy of the endocrine organs. Although the majority of thyroid cancer patients experience positive outcomes, anaplastic thyroid carcinoma is considered one of the most aggressive malignancies. Current therapeutic regimens do not confer a significant survival benefit, and new therapies are urgently needed. Oncolytic herpes simplex virus (oHSV) may represent a promising therapy for cancer. In the present study, we investigated the therapeutic effects of a third-generation HSV vector, G47Δ, on various human thyroid carcinoma cell lines in vitro. Two subcutaneous (s.c.) models of anaplastic thyroid carcinoma were also established to evaluate the in vivo anti-tumor efficacy of G47Δ.
Materials And Methods:
The human thyroid carcinoma cell line ARO, FRO, WRO, and KAT-5, were infected with G47Δat different multiplicities of infection (MOIs) in vitro. The survival rates of infected cells were calculated each day. Two s.c. tumor models were established using ARO and FRO cells in Balb/c nude mice, which were intratumorally (i.t.) treated with either G47Δor mock. Tumor volumes and mouse survival times were documented.
Results:
G47Δ was highly cytotoxic to different types of thyroid carcinomas. For ARO, FRO, and KAT-5, greater than 30% and 80% of cells were killed at MOI=0.01 and MOI=0.1, respectively on day 5. WRO cells displayed modest sensitivity to G47Δ, with only 21% and 38% of cells killed. In the s.c. tumor model, both of the anaplastic thyroid carcinoma cell lines (ARO and FRO) were highly sensitive to G47Δ G47Δ significantly inhibited tumor growth and prolonged the survival of mice bearing s.c. ARO and FRO tumors.
Conclusions:
The oHSV G47Δ can effectively kill different types of human thyroid carcinomas in vitro. G47Δ significantly inhibited growth of anaplastic thyroid carcinoma in vivo and prolonged animal survival. Therefore, G47Δ may hold great promise for thyroid cancer patients.
Insights
Oncolytic herpes simplex virus (oHSV) G47Δ effectively kills thyroid cancer cells in vitro and inhibits tumor growth in vivo. This promising therapy significantly improves survival for anaplastic thyroid carcinoma models.
Area of Science:
- Oncolytic virotherapy
- Cancer research
- Molecular oncology
Background:
- Thyroid carcinoma is a common endocrine malignancy, with anaplastic thyroid carcinoma being particularly aggressive.
- Current treatments offer limited survival benefits for aggressive forms of thyroid cancer.
- Oncolytic herpes simplex virus (oHSV) presents a potential novel therapeutic strategy.
Purpose of the Study:
- To investigate the therapeutic potential of the third-generation oHSV vector, G47Δ, against human thyroid carcinoma cell lines in vitro.
- To evaluate the in vivo anti-tumor efficacy of G47Δ in subcutaneous models of anaplastic thyroid carcinoma.
Main Methods:
- Infection of human thyroid carcinoma cell lines (ARO, FRO, WRO, KAT-5) with G47Δ at various multiplicities of infection (MOIs).
- Assessment of cell survival rates post-infection.
- Establishment of subcutaneous tumor models in mice using ARO and FRO cells.
- Intratumoral treatment of tumor models with G47Δ or mock, followed by monitoring of tumor volume and animal survival.
Main Results:
- G47Δ demonstrated high cytotoxicity against ARO, FRO, and KAT-5 thyroid carcinoma cells, with significant cell death observed at low MOIs.
- WRO cells showed moderate sensitivity to G47Δ treatment.
- In vivo studies confirmed that G47Δ significantly inhibited tumor growth and prolonged survival in mice bearing anaplastic thyroid carcinoma xenografts.
Conclusions:
- The oHSV G47Δ effectively eliminates diverse human thyroid carcinoma cell types in vitro.
- G47Δ exhibits significant anti-tumor activity and improves survival in preclinical models of anaplastic thyroid carcinoma.
- G47Δ holds considerable promise as a future therapeutic option for patients with thyroid cancer.
